Anna Krilova

A phase I dose-escalation study of IMAB362 (Zolbetuximab) in patients with advanced gastric and gastro-oesophageal junction cancer

Uğur Şahin, Martin Schüler, Heike Richly et al. · European Journal of Cancer · 2018 · 155 citations · Full text

IMAB362 plus zoledronic acid (ZA) and interleukin-2 (IL-2) in patients (pts) with advanced gastroesophageal cancer (GEC): Clinical activity and safety data from the PILOT phase I trial.

Uğur Şahin, Salah‐Eddin Al‐Batran, Wael Hozaeel et al. · Journal of Clinical Oncology · 2015 · 20 citations

Esophageal Cancer, Cancer Management, Immunology +22

Safety, tolerability, and efficacy of the first-in-class antibody IMAB362 targeting claudin 18.2 in patients with metastatic gastroesophageal adenocarcinomas.

Martin Schüler, Zanete Zvirbule, Florian Lordick et al. · Journal of Clinical Oncology · 2013 · 19 citations

Esophageal Cancer, Immunology, Immunoediting +22

Efficacy and Safety of Multiple Doses of Imab362 in Patients with Advanced Gastro-Esophageal Cancer: Results of a Phase Ii Study

Tanja Trarbach, Martin Schüler, Zanete Zvirbule et al. · Annals of Oncology · 2014 · 18 citations · Full text

Esophagus, Esophageal Cancer, Gastrointestinal Oncology +9